Envestnet Portfolio Solutions Inc. Has $712,000 Stock Holdings in ADMA Biologics Inc $ADMA

Key Points

• Envestnet Portfolio Solutions Inc. increased its stake in ADMA Biologics by 223%, owning 39,084 shares worth $712,000 as of the latest SEC filing.
• ADMA Biologics reported a Q2 earnings beat with earnings per share of $0.15, exceeding analysts' expectations of $0.14, and a revenue increase of 13.8% year-over-year.
• Several institutional investors, including Cetera Investment Advisers and Blue Trust Inc., have recently adjusted their positions in ADMA Biologics, contributing to a total institutional ownership of 75.68%.

Envestnet Portfolio Solutions Inc. raised its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 223.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 39,084 shares of the biotechnology company's stock after buying an additional 26,982 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in ADMA Biologics were worth $712,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Cetera Investment Advisers grew its position in ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after acquiring an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after acquiring an additional 711 shares in the last quarter. Blue Trust Inc. grew its position in ADMA Biologics by 53.6% in the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 964 shares in the last quarter. Concurrent Investment Advisors LLC grew its position in ADMA Biologics by 9.6% in the second quarter. Concurrent Investment Advisors LLC now owns 11,095 shares of the biotechnology company's stock worth $202,000 after acquiring an additional 973 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in ADMA Biologics by 15.5% in the second quarter. GAMMA Investing LLC now owns 7,613 shares of the biotechnology company's stock worth $139,000 after acquiring an additional 1,024 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $14.69 on Tuesday. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The firm's fifty day simple moving average is $15.96 and its 200 day simple moving average is $18.33. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $3.51 billion, a PE ratio of 17.08 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the business posted $0.13 EPS. ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. On average, sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "buy (b-)" rating on shares of ADMA Biologics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.